Dimensional Fund Advisors LP decreased its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 13.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,642,281 shares of the company’s stock after selling 412,982 shares during the period. Dimensional Fund Advisors LP owned about 3.53% of Myriad Genetics worth $121,546,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of MYGN. BlackRock Inc. raised its position in Myriad Genetics by 3.5% in the 3rd quarter. BlackRock Inc. now owns 11,466,610 shares of the company’s stock valued at $527,464,000 after purchasing an additional 383,089 shares in the last quarter. Frontier Capital Management Co. LLC raised its position in Myriad Genetics by 8.4% in the 3rd quarter. Frontier Capital Management Co. LLC now owns 2,575,754 shares of the company’s stock valued at $118,485,000 after purchasing an additional 198,819 shares in the last quarter. Acadian Asset Management LLC raised its position in Myriad Genetics by 2.6% in the 3rd quarter. Acadian Asset Management LLC now owns 2,387,166 shares of the company’s stock valued at $109,812,000 after purchasing an additional 59,446 shares in the last quarter. Northern Trust Corp raised its position in Myriad Genetics by 2.7% in the 2nd quarter. Northern Trust Corp now owns 1,801,882 shares of the company’s stock valued at $67,337,000 after purchasing an additional 47,994 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in Myriad Genetics by 6.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 910,032 shares of the company’s stock valued at $41,861,000 after purchasing an additional 55,974 shares in the last quarter. 99.80% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have recently weighed in on MYGN. BidaskClub lowered Myriad Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday. Goldman Sachs Group raised Myriad Genetics from a “sell” rating to a “neutral” rating and raised their target price for the stock from $28.00 to $32.00 in a research report on Friday, November 30th. TheStreet lowered Myriad Genetics from a “b” rating to a “c” rating in a research report on Thursday, November 8th. ValuEngine lowered Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, November 8th. Finally, Deutsche Bank raised their target price on Myriad Genetics from $37.00 to $43.00 and gave the stock a “hold” rating in a research report on Monday, November 5th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. Myriad Genetics currently has a consensus rating of “Hold” and a consensus price target of $41.90.
Shares of NASDAQ MYGN opened at $31.51 on Friday. The company has a current ratio of 3.17, a quick ratio of 2.83 and a debt-to-equity ratio of 0.23. Myriad Genetics, Inc. has a fifty-two week low of $27.27 and a fifty-two week high of $50.44. The stock has a market cap of $2.36 billion, a PE ratio of 26.26, a price-to-earnings-growth ratio of 1.83 and a beta of 0.36.
Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Tuesday, November 6th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.13. Myriad Genetics had a return on equity of 10.07% and a net margin of 7.07%. The business had revenue of $202.30 million for the quarter, compared to analyst estimates of $203.20 million. During the same quarter last year, the company earned $0.26 EPS. The business’s quarterly revenue was up 13.1% on a year-over-year basis. Equities analysts forecast that Myriad Genetics, Inc. will post 1.5 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Dimensional Fund Advisors LP Decreases Position in Myriad Genetics, Inc. (MYGN)” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/12/08/dimensional-fund-advisors-lp-decreases-position-in-myriad-genetics-inc-mygn.html.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.